Advertisement

Topics

China adds 17 oncology drugs to the NRDL( National Reimbursement Drug List) with an avg price cut of 56.7% $AZN Tagrisso -70% $PFE Xalkori -68% $NVS Tasigna -68% $JNJ Imbruvica -65% $CELG $BGNE Vidaza -60% $PFE Sutent -55% Takeda Ninlaro -46% Bayer Stiva

08:48 EDT 10 Oct 2018 | Andy Biotech

China adds 17 oncology drugs to the NRDL( National Reimbursement Drug List) with an avg price cut of 56.7% Tagrisso -70% Xalkori -68% Tasigna -68% Imbruvica -65% Vidaza -60% Sutent -55% Takeda Ninlaro -46% Bayer Stivarga -44% (h/t Nomura)

Original Article: China adds 17 oncology drugs to the NRDL( National Reimbursement Drug List) with an avg price cut of 56.7% $AZN Tagrisso -70% $PFE Xalkori -68% $NVS Tasigna -68% $JNJ Imbruvica -65% $CELG $BGNE Vidaza -60% $PFE Sutent -55% Takeda Ninlaro -46% Bayer Stiva

NEXT ARTICLE

More From BioPortfolio on "China adds 17 oncology drugs to the NRDL( National Reimbursement Drug List) with an avg price cut of 56.7% $AZN Tagrisso -70% $PFE Xalkori -68% $NVS Tasigna -68% $JNJ Imbruvica -65% $CELG $BGNE Vidaza -60% $PFE Sutent -55% Takeda Ninlaro -46% Bayer Stiva"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Searches Linking to this Story